BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fareston toremifene citrate regulatory update

FDA updated the label for breast cancer drug Fareston toremifene citrate to include a boxed warning about the risk of a prolonged QTc interval in patients receiving the drug. Prolongation of the QTc interval could lead to torsades de pointe...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >